bendamustine hydrochloride has been researched along with cc-292 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Amador, V; Aymerich, M; Campo, E; Colomer, D; Delgado, J; Giró, A; Hanna, BS; Lee-Vergés, E; Lichter, P; López-Guerra, M; Pérez-Galán, P; Rodríguez, ML; Rodríguez, V; Rosich, L; Seiffert, M; Vidal-Crespo, A; Villamor, N; Yazdanparast, H | 1 |
1 other study(ies) available for bendamustine hydrochloride and cc-292
| Article | Year |
|---|---|
Selective BTK inhibition improves bendamustine therapy response and normalizes immune effector functions in chronic lymphocytic leukemia.
Topics: Acrylamides; Adult; Agammaglobulinaemia Tyrosine Kinase; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; Bone Marrow; Disease Models, Animal; Drug Screening Assays, Antitumor; Drug Synergism; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Middle Aged; Primary Cell Culture; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrimidines; Tumor Cells, Cultured | 2019 |